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ABSTRACT
Acute myeloid leukemia (AML) is a heterogeneous hematological malignancy 
whose incidence is growing in developed countries. In the relapse setting, very 
limited therapeutic options are available and in most cases only palliative care can 
be offered to patients. The effect of a composite formulation that contains several 
antioxidants, Ocoxin Oral solution (OOS), was tested in this condition. When analyzed 
in vitro, OOS exhibited anti-AML action that was both time and dose dependent. In 
vivo OOS induced a ralentization of tumor growth that was due to a decrease in cell 
proliferation. Such effect could, at least partially, be due to an increase in the cell 
cycle inhibitor p27, although other cell cycle proteins seemed to be altered. Besides, 
OOS induced an immunomodulatory effect through the induction of IL6. When tested 
in combination with other therapeutic agents normally used in the treatment of AML 
patients, OOS demonstrated a higher antiproliferative action, suggesting that it may 
be used in combination with those standard of care treatments to potentiate their 
antiproliferative action in the AML clinic.
INTRODUCTION
Acute myeloid leukemia (AML) is a complex and 
heterogeneous hematological malignancy in which a 
multipotent hematopoietic stem cell or progenitor cell will 
be transformed to a leukemia stem cell as a result of the 
accumulation of genomic alterations [1]. AML is a disease 
predominantly of adults with a median age at diagnosis 
of 69 years [2, 3]. Probably due to the general population 
aging or to the fact that AML can also appear as a second 
cancer in patients previously treated with chemo or 
radiotherapy [4, 5], its incidence is rising in developed 
countries. Despite recent advances in its diagnosis and 
treatment, up to 75% of the patients will die of this disease 
[6]. On the other hand, for patients with relapsed AML, 
treatment options are very limited and in most of the cases 
only palliative care can be offered.
In the past few years, multiple studies have 
demonstrated that the co-administration of combination of 
various antioxidants with conventional chemotherapy or 
radiotherapy results in significant antitumor synergism and 
an inhibition of the toxicity of conventional therapy [7, 
8]. Thus, while the pure compounds are not available for 
use in the oncology clinic, commercial formulations which 
include some of these molecules offer the possibility to 
incorporate them easily and safely to the treatments 
commonly used to treat certain neoplasias [9]. Such is the 
case of Ocoxin Oral Solution (OOS), an oral nutritional 
supplement that includes recognized anti-cancer 
compounds. OOS contains green tea polyphenols such 
as epigallocatechin 3-gallate, vitamin B6 and vitamin C, 
three products whose anticancer action has been proven in 
several studies [8, 10]. OOS also contains cinnamic acid, 
a compound which may inhibit tumor growth [11], as well 
as glycyrrhizinic acid, whose action as anti-inflammatory 
and immunomodulator has been reported [12].
OOS is being currently investigated in clinical 
trials as part of the treatment for several types of cancer, 
mainly associated with chemotherapy and radiotherapy. In 
these studies, an improvement in the quality of life of the 
patients has been reported [13]. Although the mechanism 
of action of OOS is largely unknown, a recent report has 
demonstrated the antitumoral action of OOS in preclinical 
models of HER2+ breast cancer [14]. In these models, 
OOS provoked cell cycle blockage by the upregulation 
of p27 and downregulation of cyclin D1 as well as an 
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increase in apoptotic cell death. Moreover this formulation 
potentiated the action of lapatinib, a HER2 inhibitor used 
in breast cancer clinic [14].
Based on these previous results, the effects of OOS 
on preclinical models of AML were explored. Its potential 
antiproliferative action on several AML cell lines was 
initially tested in vitro. Later on, OOS effects in vivo were 
determined on a xenograft model in which the AML cell 
line HEL was used to generate the tumors. In that context, 
OOS reduced tumor growth in vivo. Moreover in this 
system cell cycle blockage was also linked to an increase 
in p27. Finally, combination studies aimed at evaluating if 
OOS could augment the efficacy of standard of care drugs 
used in AML clinic showed that this compound potentiates 
the antitumoral action of those drugs, giving the rationale 
to explore its clinical value on AML patients.
RESULTS
Effect of OOS on the proliferation of AML 
cell lines
The in vitro action of OOS was initially evaluated 
on several AML cell lines. With this purpose, the AML cell 
lines HEL, HL60 and KG1 were grown in the presence of 
increasing doses of OOS diluted into the culture medium 
and their proliferation was evaluated in MTT assays 
at different days of treatment. OOS decreased MTT 
metabolization in the three cell lines tested (Figure 1). 
Moreover, this effect was more evident at longer 
incubation times (Figure 1D). The IC50 values ranged from 
1/10-1/15 at 24 hours to up to 1/137 at 96 hours for the 
HEL cell line. Comparing the three cell lines tested, HEL 
cells were the most sensitive to the action of OOS at the 
different times and concentrations tested.
Effect of OOS in combination with anti-AML 
treatments
In most of the cases, the success of antitumor 
therapies is based on the combination of different agents 
[15]. For this reason we wondered if the combination 
of OOS with drugs commonly used in the AML clinic 
could improve their antitumor effect. Thus, OOS was 
administered in vitro to HEL cells alone (dilution 
factor 1/50), or in combination with Ara C (250 nM), 
Doxorubicin (DXR, 100 nM) or Fludarabine (Fluda, 250 
nM). In all the three cases the combination was more 
effective inhibiting the cell growth than the independent 
treatment with any of the agents (Figure 2).
In vivo efficacy of OOS in AML murine models
Given the action of OOS in vitro, we explored 
whether this in vitro effect could translate in vivo. With 
that purpose we used a xenograft murine model to 
determine the effect of OOS treatment once the tumors 
have already been established. CB17-SCID athymic mice 
were orthotopically injected with the AML cell line HEL 
and when tumors were palpable, animals were randomized 
to 4 different groups to orally receive water or increasing 
amounts of OOS: 100, 200 or 300 μl OOS per 20 g of 
animal weight. Initially, tumors included in the four groups 
had a similar volume (53±4.9; 56±5.4; 53±4.9 and 52±3.1 
mm3, mean ± SEM, respectively). After 17 days of daily 
oral treatment with OOS (Monday to Friday), a decrease 
in the growth of the tumors was observed (figure 3A and 
data not shown). Thus the mean tumor volume of control 
mice was 484±75.8 mm3, as compared with 222±37.3, 
207±66.5 or 232±61.9 mm3 corresponding to 100, 200 
or 300 μl OOS, respectively. The mean body weight of 
control or treated mice did not decrease throughout the 
duration of the experiment (figure 3B and data not shown), 
indicative of no significant toxicity of OOS in the different 
experimental conditions. Thus, at the day of sacrifice, 
mean body weight in control mice was 21.3±1 grams 
compared to 18.9±0.6, 19.5±0.5 and 19.5±0.3 grams in 
the different OOS treated groups.
Effect of OOS on circulating cytokines
As mentioned above, some components of OOS 
such as glycyrrhizinic acid exert immunomodulatory 
actions [12]. Because of this and the relevant role of the 
immune system in the control of tumor progression, we 
explored whether this formulation could affect immune 
system properties through the measurement of cytokine 
levels in mice circulating blood. Thus, the levels of IL-6, 
IL-10, IFNγ, MCP-1, TNFα and IL12p70 were measured 
in the sera collected from the animals at the time of 
sacrifice. An increase in the level of IL6 was observed as 
the amount of OOS used in the treatment rose. In fact, 
significant differences for this cytokine were observed 
between the control group and those treated with 200 or 
300 μl OOS (p=0,023 or p=0,027 respectively)(Figure 4). 
The same tendency was observed for the 100 μl group but 
in this case differences were not statistically significant 
(p=0.079), probably due to the small number of animals. 
No major changes were observed in the amount of the 
other cytokines tested (Figure 4). Moreover, there was no 
correlation between those levels and the amount of OOS 
used for the treatment
Effect of OOS cell proliferation and apoptosis 
in vivo
Because OOS caused a decrease in tumor growth 
when compared to untreated controls, we questioned if 
that effect was caused by an increased cell death, a lower 
rate of proliferation or vascularization or a combination 
of any of the above. When sections of the tumors were 
stained to identify apoptotic cells, using the conventional 
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TUNEL staining technique, no differences in the number 
of apoptotic cells were observed between the different 
groups (Figure 5A).
On the other hand, when tumors develop, a blood 
supply is necessary for them to grow beyond a few 
millimeters in size [3, 16]. For this reason, the presence of 
blood vessels in the tumor can be considered an indicator 
of tumor activity and progression, and such presence can 
be assessed by staining endothelial cells with the specific 
marker CD31 [17, 18]. Even though OOS treated tumors 
grew slower, no differences in the number of cells stained 
for this marker were observed among the different groups 
(Figure 5B).
Finally, the expression of human Ki-67, a protein 
associated with cell proliferation, was evaluated. To verify 
if OOS treatment induced changes in the proliferation 
of the tumors, staining for this marker was carried out. 
Treatment with OOS induced an evident decrease in the 
percentage of Ki-67 positive cells (Figure 5C). Moreover, 
such a decrease was statistically significant when 
compared with control untreated tumors (Figure 5C).
Figure 1. Efficacy of OOS on AML cell lines in vitro. Dose-dependent effect of OOS on the proliferation of HEL, KG1 or HL60 
AML cells was assessed in vitro. Cells were incubated with OOS at the indicated dilution factors and MTT metabolization was measured 
at 24 (A), 48 (B), 72 (C) or 96 (D) hours. Mean absorbance values of untreated samples were taken as 100% and then mean values referred 
to that. Data are represented as mean ± SD of quadruplicates of an experiment that was repeated at least twice.
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To further investigate the mechanism by which 
these tumors exhibited a decrease in proliferation, the 
amount and status of several proteins involved in cell cycle 
progression was evaluated by Western Blot analysis. This 
panel of proteins included markers of the different phases 
of the cell cycle, such as Wee1, BUBR1, pHistoneH3, pRB 
or p21 and p27, or different cyclins and CDKs, (Figure 
6A). Representative tumors were chosen and lysed to 
prepare protein extracts as described in the materials 
and methods section. Proteins were separated in SDS-
PAGE gels and the membranes probed with the indicated 
antibodies. For most of the proteins analyzed, no mayor 
differences in the control versus treated tumors were 
observed. Interestingly the levels of the cell cycle inhibitor 
p27 were upregulated in tumors from animals that had been 
treated with OOS (Figure 6A and B). p27 is an inhibitor 
of the Cyclin E/Cdk2 and Cyclin D/Cdk4 complexes, and 
its higher levels would slow down cell cycle progression, 
mainly blocking the cell cycle progression through the G1 
phase. To analyze this hypothesis, HEL cells were in vitro 
treated with OOS, and the cell cycle profile was analyzed. 
In those conditions, an accumulation in the G1-phase 
population and a correlative G2-M decrease was detected 
(Figure 6C). Moreover, when p27 levels were analyzed in 
vitro in those conditions, a clear increase in this protein 
was observed in OOS treated cells (Figure 6D).
Figure 2. OOS is more effective in combination with standard of care treatments. The effect of OOS alone (1:50) or in 
combination with Ara C (250 nM, A), Doxorubicin (DXR, 100 nM, B) or Fludarabine (Fluda, 250 nM, C) were determined in MTT 
assays. The mean absorbance values of untreated samples from each were considered as 100%. Data are represented as mean ± SD of 
quadruplicates of an experiment that was repeated at least twice.
Figure 3. Efficacy of OOS on AML models in vivo. (A) OOS interferes with tumor growth. Female CB17-SCID athymic mice were 
injected with HEL cells. When tumors became palpable and were growing, they were randomized to different groups that were orally 
treated 5 days per week (Monday to Friday) with 100μl OOS/animal (■) or vehicle alone (water,♦), and tumor volumes were measured 
twice a week. Data are represented as mean tumor volume ± SEM of the animals on each group. (B) Effect of OOS on animal weight. 
Statistical significant differences are shown (*p<0.05).
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Transcriptional effect of OOS in vivo
In order to better understand the mechanisms by 
which OOS executes its action, we investigated the 
changes in gene expression profiles derived from the in 
vivo treatment with OOS. Thus, gene expression analyses 
were performed in triplicates of the tumors from control 
untreated animals and compared with those from animals 
treated with OOS that had exhibited a slower tumor 
growth. Unsupervised clustering of the gene expression 
data associated samples into two groups, control and 
OOS-treated, indicating that treatment with OOS was able 
to sufficiently change the transcriptome to make treated 
samples to diverge from the untreated control tumors 
(Figure 7A). Quantitative comparison of both conditions 
defined 150 (fold change of 1.5, Supplementary Table 1) 
deregulated genes. Of them, 33 genes were deregulated 
more than two-fold (Figure 7B). Within those genes the 
most downregulated gene after OOS treatment was the G 
protein coupled receptor 34 (GPR34) that was 2.96 times 
more expressed in the control condition. On the other 
hand the T cell receptor TARP was the most upregulated 
gene (4.77 times) after OOS treatment. Besides within 
the deregulated genes there are other genes related to 
membrane receptors or ionic channels, such as SNC9A or 
TSPAN33. Pathway analyses defined routes particularly 
affected by the treatment with OOS. A complete listing of 
the results of pathway analyses is shown in Supplementary 
figure 1. Among the routes affected were genes involved 
in cell cycle regulation, as CDK15 or RGCC, or other 
genes involved in EGFR, IGF or TGF beta signaling or 
the leukemia inhibitory factor (LIF).
DISCUSSION
In this study we have evaluated the antitumoral 
effect of OOS in AML, using both in vitro and in 
vivo models. OOS induced a clear decrease in MTT 
metabolization, indicative of antitumoral effect, in the 
different AML derived cell lines tested, and such reduction 
Figure 4. Action of OOS on immune system cytokines. At the time of sacrifice, blood from the animals under the different 
treatments was collected by intracardiac injection, and sera clarified and frozen. The amount of the indicated cytokines was determined 
by flow cytometry using a BD Cytometric Bead Array as described in the materials and methods section. The amount for each molecule 
and experimental condition are shown in the corresponding boxplots, as indicated. Statistical significant differences are shown (*p<0.05).
Oncotarget6236www.impactjournals.com/oncotarget
Figure 5. OOS induces a decrease in tumor proliferation. (A) OOS does not induce apoptotic cell death on AML tumors. For each 
experimental condition, two tumors were randomly processed for IHQ analysis and apoptotic cells were detected by tunnel staining. The 
number of apoptotic cells/field was quantified for each condition and its mean number ± SD is shown in the graph. Pictures of representative 
fields stained for this marker are shown on the right. (B) Similarly the number or endothelial cells was measured by CD31 staining. (C) 
Besides, to establish the proliferative status of the tumors, Ki67 marker was used. Pictures of representative fields stained for Ki-67 are 
shown on the right upper row and lower pictures show part of them (inset) at higher magnification. Statistical significant differences are 
shown (*p<0.05).
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was both time and dose dependent. Moreover, OOS 
reduced tumor progression in vivo in mice implanted with 
the cell line HEL, which was the most sensitive cell line to 
OOS in vitro, and was used to generate xenograft models. 
OOS treatment slowed down tumor growth without 
apparent toxicity, since the weights of the control and 
treated mice were analogous, and no detectable changes 
in their behavior were observed. Thus, OOS demonstrated 
a clear effect on AML tumor progression.
Since OOS is a nutritional supplement that includes 
recognized anti-oxidants in its formulation, chances are 
that these agents would also have a preventive action in 
vivo. In fact this action has been recently described for 
other models such as breast cancer models in which OOS 
has antitumor effects both preventive, and once the tumors 
have been established [14]. If OOS could also have such 
a preventive action on AML models should be similarly 
tested.
To gain insights into the mechanisms leading to 
the reduction of tumor burden in vivo, several studies 
were carried out. To evaluate if it was due to a reduction 
in cell duplication, an increase in cell death or both, 
sections of the tumors were stained with appropriate 
markers. There was no effect of OOS on cell death 
since no differences on the number of cells stained by 
TUNEL were observed when compared to tumors from 
untreated animals. Similarly, no differences on the 
vascularization marker CD31 were found. It was only 
when the proliferation marker Ki67 was used to stain 
the sections when significant differences were found. 
Tumors from animals treated with OOS exhibited a lower 
percentage of cells stained with this marker, pointing to a 
decrease in cell proliferation in those conditions. To better 
characterize this effect, the amount and status of different 
cell cycle markers were determined by WB. There were 
no differences in the CDKs or cyclins tested. The main 
differences were observed in the levels of p27Kip1. This 
is an inhibitor of cell cycle progression encoded by the 
CDKN1B gene and whose presence prevents the activation 
of the cyclin E-CDK2 and cyclin D-CDK4 complexes, and 
thus blocks the cell cycle at the G1 phase [19]. In fact p27 
has been described to play a role in carcinogenesis, and 
Figure 6. OOS causes accumulation of p27 and G1 arrest. (A) Quantitation of the in vivo levels of cell cycle related proteins. The 
amount of the indicated proteins in the tumors was assessed by conventional WB. (B) The amount of p27 was quantified using the NIH 
image software, and the mean ± SD of such amount is represented in the graph. (C) Cell cycle analysis of HEL cells treated for 24 hours 
with OOS (1/50 dilution). The percentage of cells in the different phases of the cell cycle is shown. (D) Action of OOS (1/50) on p27 levels. 
HEL cells were treated for 24 hours with OOS and cell extracts prepared to analyze p27 by WB. GAPDH was used as a loading control.
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Figure 7. In vivo effect of OOS on gene expression profiles. (A) Hierarchical clustering of the 6 tumors and the 37 genes deregulated 
after OOS treatment. Each row represents a gene and each column represents a tumor (1- control, 2- OOS treated). The expression level 
of each gene in each tumor is relative to its medium abundance across all the tumors and is depicted according to the color scale shown. 
Red and green indicate high or low expression levels, respectively. (B) The gene expression profile of three control tumors was compared 
to that of three tumors treated with 100 μl of OOS. A list with those genes whose expression changed above 2 times with the treatment is 
shown in the figure.
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could probably be used as a prognostic factor in different 
tumors, as well as an indicator of response to therapies 
[20]. Besides these data corroborate those found for the 
mechanism of action of OOS on breast cancer models. 
In that model OOS induces both cell death and cell cycle 
arrest in G1, this latter due to an increase in p27 levels, 
concomitant with a decrease in cyclin D1 [14].
So far, the general mechanism of OOS action is 
not clear, although it points to inhibitory effects on cell 
cycle progression. The analysis of the genes whose 
expression changed after OOS treatment identified some 
involved in cell cycle regulation and progression such 
as CDK15 or RGCC. The function of these proteins as 
cell cycle regulators is not fully known and its potential 
role in AML should be carefully analyzed in this context. 
Interestingly, OOS caused a decrease in the amount of LIF. 
This polypeptide acts by binding to the LIF receptors and 
gp130, and such binding triggers the activation of several 
signaling pathways, including the JAK/STAT, MAPK, 
and PI3K routes. In different cell types, LIF may exert 
opposite effects including stimulation or inhibition of cell 
proliferation [21].
One of the characteristics of AML is the replacement 
of normal blood cells with leukemic cells, which makes 
the patients more susceptible to infections [22, 23]. In our 
study OOS seems to stimulate the immune system through 
the production of IL6. Thus, if OOS not only blocks the 
proliferation of AML cells, but also stimulates the immune 
system, patients could benefit from this double advantage.
Most antitumor therapies rely on the combination of 
agents to increase the antitumor action of the individual 
agents [15]. In this respect, when OOS was used in 
combination with AML standard of care treatments, a 
potentiation of their antiproliferative effect was found. 
This observation would establish the rationale to test the 
therapeutic potential of OOS in AML patients alone or 
in combination with other antitumoral agents. Especial 
attention should be paid to patients with relapsed AML, 
since in them the therapeutic options are very limited 
and in most of the cases, only palliative care can be 
offered [24]. In this group of patients OOS addition to 
gold standard therapies could augment their antitumoral 
properties and be, therefore, an interesting therapeutic 
option.
MATERIALS AND METHODS
Reagents and antibodies
Cell culture media, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), hematoxylin 
and eosin were purchased from Sigma. Foetal bovine 
serum (FBS) and antibiotics were from Life Technologies 
and Immobilon P (PVDF) membranes from Millipore. 
OOS was provided by Catalysis, S.L. (Madrid, Spain). 
The Cytometric Bead Array Mouse Inflammation kit was 
purchased to BD biosciences. Other generic chemicals 
were purchased from Sigma Chemical Co., Roche 
Biochemicals or Merck.
The origin of the different antibodies used in the 
Western blotting analyses were as follows: the anti-
GAPDH, anti-p21, anti-Wee1, anti-CDC2/CDK1, anti-
pCDC2, anti-Cyclin B and anti-Cyclin D1 antibodies 
were purchased from Santa Cruz Biotechnology; the anti-
BUBR1, anti-Rb, anti-Cyclin A, anti-Cyclin D3 and anti-
Cyclin E from BD Biosciences; the anti-p27 and the anti-
pRbS780 from Cell Signaling technology; the anti-Calnexin 
from Stressgen and the anti-pHistone H3 from Millipore. 
The horseradish peroxidase-conjugated secondary 
antibodies were from Bio-Rad.
Cell culture, cell cycle and cell proliferation 
measurement
AML cell lines were grown in RPMI 1640 medium 
supplemented with 10% FBS and antibiotics. All the cell 
lines were cultured at 37°C in a humidified atmosphere 
in the presence of 5% CO2-95% air. The cell lines were 
obtained from the American Type Culture Collection, Cell 
Biology Collection (Manassas, VA), or have already been 
described [25].
For cell cycle analysis by flow cytometry, ethanol 
fixed cells were stained with 5 μg/ml propidium iodide 
(PI) and 250 μg DNAse-free RNAse. A total of 50,000 
cells were acquired in the propidium iodide gate by using 
a BD AccuriTM C6 flow cytometer and the C6 software 
(BD Biosciences).
Cell proliferation of AML cells was examined 
using a modified MTT metabolization assay [26]. Briefly, 
cells were plated in triplicates and, on the day of the 
experiment, MTT was added to the wells at 0.5 mg/ml 
and incubated at 37°C for 4 hours. The MTT-formazan 
crystals were dissolved in isopropanol-HCl and the 
absorbance of the samples was recorded at 570 nm using 
a Tecan spectrophotometer with the X-Fluor 4 software. 
At least three wells were analyzed for each condition, 
and the results are presented as the mean +/- SD of a 
representative experiment repeated at least twice.
In vivo experiments
For animal studies, twenty-four 7-week-old 
female athymic mice (CB17-SCID) were purchased 
from Charles River Laboratories (Wilmington, MA), 
and kept in pathogen free housing at our Institutional 
Animal Care Facility. One week later, 3x106 HEL cells 
resuspended in 50 μl of RPMI-1640 and 50 μl of Matrigel 
were subcutaneously injected into the right caudal flank 
of each animal. When tumors became palpable, mice 
were randomized into four groups (n = 6 per group), that 
were administered the different treatments: control group 
(receiving the vehicle alone) or various concentrations of 
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OOS, including 100 μl, 200 μl, or 300 μl per mouse (20 
g). Treatments were administered for 17 days with a daily 
schedule (Monday to Friday) by oral gabage. Mice were 
weighted and tumors measured twice a week with a digital 
caliper (Proinsa, Vitoria, Spain). Tumor volumes were 
calculated using the following formula: V = (L/2) x (W/2)2 
x 4/3 x π, where V = volume (cubic mm), L = length (mm) 
and W = width (mm). At the time of sacrifice, tumor tissue 
was resected and immediately frozen at –80°C. Besides, 
blood was extracted by intracardiac injection, and the sera 
collected and frozen at -80°C for further analyses.
Protein extraction and Western blotting (WB)
Frozen mice tumor samples were minced, washed 
with phosphate-buffered saline (PBS), and homogenized 
in ice-cold lysis buffer [26], that had been supplemented 
with 10X protease inhibitors using a tight-fitting Dounce 
homogenizer. This homogenate was centrifuged at 4°C, 
and the supernatants were transferred to new tubes for 
protein concentration measurement by Bradford assay. 
Boiled samples were separated on 6%–15% SDS-PAGE 
gels, depending on the molecular weight of the proteins 
to be analyzed, and after electrophoresis, proteins in gels 
were transferred to PVDF membranes and WB performed 
as previously described [26]. Bands were visualized 
by using ECL Western Blotting Detection System 
(GE Healthcare, Buckinghamshire, United Kingdom). 
Similarly, protein extracts from OOS-treated cells were 
prepared and analyzed.
Analysis of circulating cytokines
To determine the amount of different cytokines 
present in mice serum samples, the BDTM CBA Mouse 
Inflammation kit was used, following the providers´ 
instructions. Briefly, sera to be tested were thawn on 
ice while in parallel the capture beads specific for the 
cytokines were properly mixed and 50 μl added to the 
assay tubes. On top of them, either 50 μl of the unknown 
samples, or the mouse inflammation standards previously 
prepared by serial dilution were added and incubated 
in the dark for 2 hours at room temperature. One ml 
wash buffer was added and the beads spun down. After 
aspirating the supernatant, pellets were resuspended in 300 
μl wash buffer and samples analyzed in a BD AccuriTM C6 
cytometer. Data were further analyzed using the BD FCAP 
ArrayTM software version 3.0.
Histological and immunohistochemistry (IHC) 
analyses
Representative tumor areas were fixed in formalin, 
paraffin embedded, cut in 2- to 3-μm sections, and either 
stained with hematoxylin and eosin or prepared for IHC, 
that was performed as previously described [27]. Thus, 2 
cell conditioning periods of 8 min at 95°C and 4 min at 
100°C on hot plate using TRIS-EDTA (pH=8) buffer were 
performed on previously dewaxed formalin-fixed paraffin-
embedded sections. Sections were then incubated with the 
anti-Ki67 or anti-CD31 antibodies, and the staining was 
performed with the IHC 3,3´-diaminobenzidine MAPO 
system (Ventana Medical Systems). For the TUNEL 
staining the In Situ Cell Death Detection Kit (Roche 
Mannheim, Germany) was used, and counterstained with 
4´,6-diamino-2-phenylindole. Results were evaluated 
blinded to clinicopathologic and molecular data. The 
number and intensity of immunoreactive cells were 
evaluated in at least ten randomly selected fields. These 
procedures were done by independent personnel of the 
pathology unit of our center. Conflict measurements were 
solved by consensus.
RNA isolation, cDNA synthesis and microarray 
hybridization and analysis
After thawing, tumors were excised and lysed 
in Trizol Reagent (Life Technologies), according to 
the manufacturer´ instructions. Briefly, tumors were 
homogenized (Dispomix, L&M Biotech, Holly Springs, 
NC, USA) and incubated in the Trizol solution for 2 
minutes at room temperature, before the addition of 
chloroform. Tubes were vigorously shaken and the 
different phases separated by centrifugation. The upper, 
aqueous phase was recovered and the RNA present 
precipitated with isopropyl alcohol. Once washed in 
70% ethanol the resultant RNA was column-purified 
(Qiagen, RNeasy mini kit) and its integrity was assessed 
(Agilent 2100 Bioanalyzer, Agilent). Biotinylated 
complementary RNA was then synthesized (Enzo Life 
Sciences) and hybridized to HG-U133 plus 2.0 GeneChip 
oligonucleotide arrays (Affymetrix). Quantitation of 
fluorescence intensities of probesets was done using the 
GenArray Scanner (Hewlett Packard). Unprocessed files 
were normalized using the RMA algorithm implemented 
in the Affimetrix Expression Console. Differentially 
expressed genes were identified using significant analysis 
of microarrays, selecting all genes with a value of Q≤0.05. 
Microarray data are now available through the GEO 
repository database (reference GSE75174).
Statistical analysis
Each condition was analyzed in triplicate or 
quadruplicate and data are presented as the mean ± SD of 
at least three independent experiments. Comparisons of 
continuous variables between two groups were performed 
using two-sided Student´s t test. Differences were 
considered to be statistically significant when P values 
were less than 0.05.
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